Magid Abou-Gharbia, Ph.D.
Magid Abou-Gharbia, Ph.D, FRSC is currently Laura H. Carnell Professor of Medicinal
Chemistry and Founding Director of the Moulder Center for Drug Discovery Research
(MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA. As the Founding
Director, he was responsible for Setting and implementing Moulder Center research strategies to
bridging preclinical research with clinical research “from Bench to Patient-Bedside” and
promoting the school’s research and entrepreneurial enterprise. Prior to joining Temple
University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice
President Discovery Research. In my role I directed research of 500 scientists at 4 US sites (PA,
NJ, NY and MA) and 150 Chemists in Hyderabad, India. Abou-Gharbia’s research team efforts
resulted in the Discovery of 10-marketed drugs across multiple therapeutic areas including two
drugs for treatment of depression Effexor and Pristiq and four Drugs for treatment of Cancer
and increasing the life expectancy of patients in need (Antibody Drug Conjugate Mylotarg, m-
TOR inhibitor Torisel, Two Kinase inhibitors Bosulif and Neratinib).
His research contributions in the past 15 years at Temple University resulted in establishing
Moulder Center for Drug Discovery Research (https://www.youtube.com/watch?v=2yotuH6ZU0c),
a State-of-the-Art academic Drug discovery Center. Moulder Center’s accomplishments included
receiving several research grants and contract research (>$30M), the publications of numerous
research papers in peer-reviewed journals, the filing of over 35 US patents and the formation of 4
spin off companies based on licensing of his Center’s IP to external companies. Magid received
numerous awards for his scientific achievements and serves on the Scientific Advisory Board of
several companies and Scientific and professional societies and has adjunct professor
appointments at several universities in the US and abroad. His career research achievements
resulted in more than 128 US patents, over 350 worldwide Patents, 325 publications, invited
lectures and presentations.
Current Research Activity: Medicinal Chemistry and Drug Design, particularly in the areas of
glutamate Transporters Enhancers for treatment of cocaine addiction, Alcohol use and
cerebral palsy
, epigenetic modulators anti-cancer agents, anti-infectives and drugs for treating
neuronal disorders
.